News

Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

March 14, 2024
Siolta Therapeutics, a clinical-stage biotech company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, reflects enthusiasm for Siolta's approach to developing live microbiome-based therapeutics and involved all existing...

Turbocharged CAR-T cells melt tumours in mice — using a trick from cancer cells

February 07, 2024
Immune cells armed with a mutation first identified in cancer cells gain potency but don’t turn cancerous themselves. “Natural T-cell function isn’t good enough. We need to explore the extremes of T-cell function,” says Kole Roybal, an immunologist at the University of California, San Francisco,...

Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution

January 18, 2024
Aclarion, a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (cLBP), announced today the product release of Nociscan 2.6 which includes support for additional leading...

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262

January 08, 2024
Sana Biotechnology, a company focused on changing the possible for patients through engineered cells, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to initiate a study of SC262 in patients with relapsed or refractory...

EndeavorRx, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17

December 18, 2023
Akili, a leading digital medicine company, today announced that it has received authorization from the U.S. Food and Drug Administration (FDA) to expand the label for EndeavorRx® from 8 to 12-year-old patients with primarily inattentive or combined-type ADHD who have a demonstrated attention issue...

BeeKeeperAI Expands Privacy-Enhancing Innovation with New Patent, New Product, and New Advantages to Accelerate Responsible AI in Healthcare

December 14, 2023
BeeKeeperAI, a pioneer in privacy-enhancing, multi-party collaboration software, today announced the next step in its innovation strategy for EscrowAI™ with automated, privacy-enhancing workflows to advance the responsible development and deployment of AI for healthcare. Dr. Michael Blum is the...

Encellin Closes $9.9M Financing Led by Khosla Ventures to Advance Cell Encapsulation Platform for Endocrine Disorders

December 13, 2023
Encellin, a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing round led by Khosla Ventures, with participation from Y Combinator. This technology was licensed from Dr. Tejal Desai’s lab where...

Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform

December 13, 2023
Shinobi Therapeutics, the biotechnology company developing a new class of immune evasive iPS-T cell therapies, today announced that it has closed a $51 million Series A financing. The oversubscribed round was led by EQT Life Sciences, F-Prime Capital, and Eight Roads Ventures Japan, with...

Chroma Medicine Highlights Data Demonstrating Durable Multiplex Epigenetic Editing to Enhance Allogeneic CAR T at 65th ASH Annual Meeting

December 11, 2023
Chroma Medicine, a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented data demonstrating the potential of its multiplex epigenetic editing platform to enhance functional allogeneic chimeric antigen receptor (CAR) T cells at the American Society of...

Pages